🇺🇸 FDA

Intelligence · Clinical Pipeline

Autoimmune & immunology R&D Pipeline

Autoimmune, rheumatology, and immunology biologics in clinical development.

Programs
987

Quick answer

Autoimmune & immunology: NovaPharmaNews indexes 987 autoimmune & immunology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Autoimmune, rheumatology, and immunology biologics in clinical development.

Top sponsors

Page 15 of 21

  1. Zasocitinib

    Takeda

    Crohn's Disease

    phase 2 small molecule active

    2 trials

  2. Zilretta

    Pacira Ireland Limited

    Osteoarthritis of Hip

    phase 2 small molecule terminated

    1 trial

  3. Zr89

    Disc Medicine

    giant cell arteritis, rheumatoid arthritis

    phase 2 small molecule active

    1 trial

  4. [68Ga]FAPI-46

    Disc Medicine

    giant cell arteritis - polymyalgia rheumatica spectrum disease

    phase 2 small molecule active

    1 trial

  5. amobarbital/Gel-One (one dose)

    United Therapeutics Europe Ltd

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

  6. bimekizumab

    Lacuna Pharma Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  7. corticosteroids

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Severe Colitis (ASC)

    phase 2 small molecule active

    1 trial

  8. cyclophosphamide

    Ultragenyx UK Limited

    Anemia, Hemolytic, Autoimmune

    phase 2 small molecule completed

    1 trial

  9. cytarabine

    Ultragenyx UK Limited

    Lupus Erythematosus, Systemic

    phase 2 small molecule completed

    1 trial

  10. edratide

    Teva Pharma GmbH

    Systemic Lupus Erythematosus

    phase 2 small molecule terminated

    1 trial

  11. etiprednol dicloacetate

    Teva Pharma GmbH

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  12. glatiramer acetate

    Teva Pharma GmbH

    Crohns Disease

    phase 2 small molecule active

    1 trial

  13. honeybee venom (Apitoxin (Korea) Apitox (USA))

    Apimeds Pharmaceuticals US

    Osteoarthritis of the Knee

    phase 2 small molecule completed

    1 trial

  14. infloran

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Enterocolitis, Necrotizing

    phase 2 other terminated

    1 trial

  15. mesenchymal stem cell

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lupus Nephritis

    phase 2 mab active

    1 trial

  16. nicotinamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cutaneous Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  17. pectin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  18. rituximab

    Chinese University of Hong Kong

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  19. sarilumab

    Sanofi-aventis Healthcare Pty Ltd

    Systemic Juvenile Idiopathic Arthritis (sJIA)

    phase 2 small molecule active

    1 trial

  20. tamuzimod, tamuzimod, tamuzimod, VTX002 placebo film-coated tablets matching VTX002, tamuzimod

    Lacuna Pharma Pty Ltd

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  21. tulisokibart, Placebo to MK-7240

    Merck Sharp and Dohme

    Psoriatic arthritis​​

    phase 2 small molecule active

    1 trial

  22. tulisokibart, Placebo to MK-7240 (tulisokibart)

    Merck Sharp and Dohme

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  23. vilamakitug

    XBiotech Germany GmbH

    Axial Spondyloarthritis

    phase 2 small molecule active

    1 trial

  24. 1% icotinib hydrochloride cream

    Betta Pharmaceuticals Co.,

    Psoriasis

    phase 1 small molecule completed

    1 trial

  25. 50 mg LX3305 QD

    LEXICON PHARMACEUTICALS, INC.

    Rheumatoid Arthritis

    phase 1 small molecule completed

    1 trial

  26. 608

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Moderate to Severe Plaque Psoriasis

    phase 1 small molecule active

    1 trial

  27. A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients with Ulcerative Colitis

    Lacuna Pharma Pty Ltd

    Ulcerative colitis

    phase 1 other active

    1 trial

  28. A Long-Term Follow-up Study for Subjects Previously Treated with A Century Therapeutics Cellular Therapy Product

    Century Therapeutics

    Hematological or solid tumor malignancies or autoimmune diseases

    phase 1 other active

    1 trial

  29. A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2)

    Celgene Europe Limited

    Myasthenia gravis (MG), Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis (RMS)

    phase 1 other active

    1 trial

  30. A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases (Breakfree-1)

    Celgene Europe Limited

    Systemic Sclerosis, Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathy, Systemic Lupus Erythematosus (SLE)

    phase 1 other active

    1 trial

  31. A Phase 1 Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases

    Bristol-Myers Squibb Australia Pty Ltd

    Systemic Sclerosis, Idiopathic Inflammatory Myopathy, Rheumatoid Arthritis, Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  32. A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pimozide after Multiple Dose Administration in Subjects with Rheumatoid Arthritis

    Lacuna Pharma Pty Ltd

    rheumatoid arthritis

    phase 1 other active

    1 trial

  33. A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE)

    Cullinan Therapeutics

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  34. A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA)

    Cullinan Therapeutics

    Treatment-Refractory Rheumatoid Arthritis

    phase 1 other active

    1 trial

  35. A Single-Arm, Open-Label, Phase 1 Study to Determine the Safety, Tolerability and Preliminary Efficacy of Obecabtagene Autoleucel in Patients with Severe, Refractory Systemic Lupus Erythematosus

    Autolus GmbH

    Severe, Refractory Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  36. A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese and Japanese Participants, and Participants with Interstitial Lung Disease Associated with Connective Tissue Disease (CTD-ILD)

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  37. A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants with Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)

    AbbVie Deutschland GmbH & Co. KG

    Systemic Lupus Erythematosus, Sjogren's disease

    phase 1 other active

    1 trial

  38. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants with Systemic Lupus Erythematosus

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE)

    phase 1 other active

    1 trial

  39. A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants with Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

    AstraZeneca AB

    Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies

    phase 1 other active

    1 trial

  40. A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 are Tolerated and Act in the Body of Healthy Adults

    Pfizer Australia Pty Ltd

    Rheumatoid arthritis and Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  41. A clinical study of MK-1045 in people with lupus or rheumatoid arthritis (MK-1045-004)

    Merck Sharp and Dohme

    Systemic lupus erythematosus, Rheumatoid arthritis

    phase 1 other active

    1 trial

  42. A clinical study of MK-2420 in healthy men (MK-2420-003)

    Merck Sharp and Dohme

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  43. A clinical study of MK-2420 in healthy people (MK-2420-002)

    Merck Sharp and Dohme

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  44. A dose-finding Phase I study of F8IL10 intra-articular treatment in Rheumatoid Arthritis

    Philogen S.p.A.

    Patients with Rheumatoid Arthritis (RA) who, despite treatment with stable doses (for at least 3 months) of disease-modifying antirheumatic drugs (DMARDs, conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for intra-articular (IA) injection in a knee, shoulder, ankle, wrist or elbow.

    phase 1 other active

    1 trial

  45. A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine Delayed Release Tablets USP 1.2 g manufactured by Sun Pharmaceutical Industries Limited, India with Mezavant (mesalamine) Delayed and Extended-Release Tablets 1.2 g product of Takeda Canada Inc., in healthy, adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    ulcerative colitis

    phase 1 other active

    1 trial

  46. A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine Delayed Release Tablets USP 1.2 g manufactured by Sun Pharmaceutical Industries Limited, India with Mezavant (mesalamine) Delayed and Extended-Release Tablets 1.2 g product of Takeda Canada Inc., in healthy, adult, human subjects under fed condition.

    Lacuna Pharma Pty Ltd

    ulcerative colitis

    phase 1 other active

    1 trial

  47. A first-in-human study to investigate safety and tolerability of SAR446959 in participants with osteoarthritis of the knee

    Sanofi-aventis Healthcare Pty Ltd

    Osteoarthritis

    phase 1 other active

    1 trial

  48. A phase 1 trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with autoimmune disease(s)

    Otsuka Beijing Research Institute

    Systemic lupus erythematosus, Immune-mediated focal segmental glomerulosclerosis, Alopecia Areata

    phase 1 other active

    1 trial

Frequently asked questions

How many autoimmune & immunology pipeline programs are tracked?

987 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.